Articles written by David Willey - Benzinga

Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant

Read the latest report on NanoViricides here

Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market

Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a century ago to just 7 per 1,000 births in 2020. However, some serious pediatric conditions continue to pose a threat.

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For

Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™ cellular drug in the next 3 to 4 months.

New Industries For Electrification: HEVI's Portfolio Of Electric Vehicles Could See Applications In A Range Of Underelectrified Industries

Greenland Technologies Holding Corporation (NASDAQ: GTEC) is bringing electrification to the heavy equipment industry under its brand HEVI Corp.

VT Markets Provides Multi-Award Winning Brokerage And Top-Tier Forex Services For Over 200,000 Active Accounts — Traders Can Get Started In Just 5 Minutes

VT Markets is a global, multi-asset brokerage company specializing in Contract for Differences (CFD) and Foreign Exchange Market (Forex) trading.

Shapeways Transforms Multi-Billion-Dollar Manufacturing Industry; Its Proprietary Software Empowers On-Demand Production

Shapeways Holdings, Inc. (NASDAQ: SHPW), a leading digital manufacturing company, is positioned to transform the global manufacturing industry.

Windtree Therapeutics (NASDAQ: WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market

Windtree Therapeutics, Inc. (NASDAQ: WINT) is a biotechnology company developing treatments for severe cardiovascular disorders.

This Company At The Intersection Of Two Multi-Billion Dollar Industries Offers A Solution To America's Biggest Mobile Source Of Air Pollutants

Greenland Technologies Holding Corporation (NASDAQ: GTEC) has seen a growth opportunity by electrifying the heavy equipment sector, and it is hoping to get a first-mover advantage as it begins rolling out its line of all-electric heavy machinery.

OLB Group (NASDAQ: OLB) Acquires Controlling Interest In Prepaid Phone Platform, Potentially Expanding Its Services For The Underbanked To An Additional 31,000 Locations

OLB Group, Inc. (NASDAQ: OLB) is a diversified payment and omnicommerce technology services provider that provides the benefits of traditional banking

As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?

Tiziana Life Sciences, Inc.

Following A Biotech Subsidiary Spin-Off, Here's A Look At Another DSS, Inc. (NYSE American: DSS) Subsidiary, This Time In A $193 Billion Industry

Premier Packaging Corp is a turnkey paperboard and folding carton packaging company that provides top-quality design, manufacturing, inventory management, and other services. Wholly owned by DSS, Inc.

Kick Start Your Day Trading Career With Apex Trader Funding, A Leading Prop Firm With Average Monthly Compensation To Traders Of $3 Million

Click here to watch Trader Bacon! Austin-based Apex Trader Funding reports that it is not only one of the largest prop trader firms in the industry but that it makes some of the largest and most consistent payouts to its large trading community.

Longeveron Announces Key Additions To Its Leadership Team And Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions

Longeveron, Inc. (NASDAQ: LGVN) is a clinical-stage biopharmaceutical company focused on therapies for age-related and life-threatening diseases.

Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon

Tiziana Life Sciences (NASDAQ: TLSA), a clinical-stage biotechnology company focused on developing immunotherapies, will soon announce the 6-month results for patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS) receiving its novel intranasal treatment, foralumab.

Study Confirms FORME's Approach To Fitness: A Deeper Look Into A Digital Fitness Company That Recently Reported Tripling Its Average Annualized Recurring Revenue Per Household

The Washington Post has highlighted a recent Japanese study on the importance of a buddy for improving fitness results. This study seems to confirm the approach taken by digital fitness company Interactive Strength Inc.

Minimal Rules, Maximized Funds? With $24 Million Paid Out In Compensation, Apex Trader Funding Has Become The Leading Futures Prop Firm

Watch the Trader Bacon show here.

Could HybriU, Ambow Education's (NYSE: AMBO) New AI-Powered Education Solution, Revolutionize The $600+ Billion Learning Market?

Ambow Education Holdings Ltd. (NYSE: AMBO) is bringing innovative artificial intelligence (AI) technology to the educational sector. It has launched HybriU, an AI-powered digital education platform that is designed to empower students and bridge the gap between academia and industry.

As ESG Requirements Promote Onshoring Of Critical Mineral Mining, This Company With Multiple Projects In World's Most Mining-Friendly Jurisdiction Could Be One To Watch

Electric vehicles (EVs) are becoming increasingly more popular as a clean energy solution, and manufacturing names like Tesla (NASDAQ: TSLA) have become associated with the meteoric rise of battery-powered vehicles.

DSS, Inc.'s (NYSE American: DSS) Subsidiary Appoints New Chief Investment Officer To Aggressively Develop Mutual Fund Business For Eventual Spinoff

DSS Wealth, Inc. has appointed Daniel Lew as its new Chief Investment Officer (CIO) and Portfolio Manager. DSS Wealth is a mutual fund and a wholly-owned subsidiary of DSS, Inc.

Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?

There have been several accelerated approvals granted to treatments for patients with Alzheimer’s disease (AD) by the Food and Drug Administration (FDA) in recent months, and there are several treatments also in development.